

## **Q4 2018 Payment Limit Report for Ophthalmology**

CMS has released the Q4 2018 drug pricing files for both average sales price (ASP) and not otherwise classified (NOC) drugs, effective **October 1, 2018**. The data used for the Q4 2018 reimbursement files is based on the Q2 2018 sales data submitted to CMS by drug manufacturers. Detailed information, including reimbursement allowables on NOC drugs, is available on the [CMS website](#). For ophthalmology its correct.

To better serve your practice, we have identified the changes to a number of widely administered drugs and calculated the percentage change over the past quarter.

<b>Drug</b>	<b>HCPCS Code</b>	<b>Billing Unit</b>	<b>Q3 2018 ASP+6%</b>	<b>Q4 2018 ASP+6%</b>	<b>% Change</b>
Aflibercept (EYLEA®)	J0178	1 mg	\$967.67	\$967.33	-0.04%
Alteplase recombinant (ACTIVASE®)	J2997	1 mg	\$87.62	\$87.78	0.18%
Bevacizumab (AVASTIN®)	J9035	10 mg	\$78.85	\$79.25	0.51%
Dexamethasone intravitreal implant	J1100	1 mg	\$0.12	\$0.11	-6.62%
Fluocinol acet intravit imp (ILUVIEN®)	J7313	.01mg	\$490.20	\$490.33	0.03%
Methylprednisolone Acetate Injection	J2920	40 mg	\$4.81	\$4.72	-1.84%
Methylprednisolone Acetate Injection	J2930	125 mg	\$6.97	\$6.94	-0.34%
Midazolam hydrochloride	J2250	1 mg	\$0.12	\$0.13	8.07%
Mitomycin	J9280	5 mg	\$144.08	\$134.25	-6.83%
Ocriplasmin (JETREA®)	J7316	.125 MG	\$1,018.70	\$836.34	-17.91%
Pegaptanib sodium (MACUGEN®)	J2503	0.3 mg	\$717.87	\$713.86	-0.56%
Ranibizumab (LUCENTIS®)	J2778	0.1 mg	\$373.50	\$373.36	-0.04%